Leqembi, a drug from Biogen and Eisai, presents a potential breakthrough for Alzheimer’s patients, particularly those in the earliest stages of the disease. Approved in July 2023, it aims to slow the progression of cognitive decline, allowing patients more time to live independently. However, the journey to accessing this treatment is fraught with challenges.
The Promise of Leqembi
Leqembi is not a cure but offers a lifeline by moderately slowing memory and cognitive decline. For patients like Missie Meeks, who was diagnosed with early-stage Alzheimer’s before her 50th birthday, the drug has been pivotal in maintaining a semblance of normalcy. “It’s extending my time of a normal life,” Meeks shared.
Challenges in Access
Despite its promise, accessing Leqembi is complex. Patients face hurdles such as insurance coverage issues, the need for diagnostic tests, and regular brain scans. The scarcity of neurologists further complicates the process. Some hospitals lack the infrastructure to support the influx of patients eligible for the treatment.
Risks and Concerns
Leqembi is associated with risks like brain swelling and bleeding, leading some doctors to be cautious in prescribing it. Dr. Julio Rojas from UCSF Health highlights the ongoing challenge of determining how best to use and monitor the drug.
Diagnosis and Eligibility
The process of diagnosing Alzheimer’s and determining eligibility for Leqembi is lengthy. It involves PET scans or spinal fluid tests to identify amyloid plaques, a hallmark of Alzheimer’s. Even after diagnosis, insurance barriers can prolong the wait for treatment.
Infusion Difficulties
Once approved, patients must receive biweekly infusions of Leqembi. However, the limited number of infusion centers poses logistical issues, especially for those living far from available clinics.
Moving Forward
Despite these obstacles, the number of patients receiving Leqembi is growing. Sales reached nearly $60 million in the first half of 2024, indicating increasing uptake. Biogen and Eisai are working on more accessible forms of the drug, including a monthly maintenance dose and a subcutaneous version.
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
→ 
→ 
→ 
→ 
→ 
→ 
→ 
